MedImmune is history.
AstraZeneca execs acknowledged today that the company is sweeping the MedImmune brand name away as CEO Pascal Soriot streamlines the R&D organization, carving the group into 2 parts.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.Free Subscription